ABOUT
Interstice Therapeutics, LLC
Mission
Interstice Therapeutics, LLC is a biotech company focused on rapid development and approval of novel 505b(2) drugs to address anticipated and/or real world branded New Drug Application (NDA) treatment adoption gaps.
LEADERSHIP
Andrew H. Isaacs
President & CEO
Thirty years proven record of achievements in leading Global Operations, Strategic Planning, New Product Development, Marketing, Business Development, Change Management, Technology Assessments and Implementation, Medical Education, Brand Launches, Sales Teams, and Technology Alliances, from concept through launch of products and added value services.
BioMedical Engineering undergraduate degree from Boston University, dual MBA/MS graduate degrees from Kean University, and Superior Product Development certificate from Harvard Business School.
CONTACT
Phone
908-229-2199
